SS Innovations: SSi Mantra Robot and Founder Background

Overview of SS Innovations and the SSi Mantra Platform

SS Innovations International, Inc. is a commercial-stage medical technology firm that develops modular robotic surgery hardware. It builds and manufactures out of India, where founder Dr. Sudhir Srivastava relocated to launch robotic-surgery programs. Dr. Srivastava founded SS Innovations to provide an alternative to capital-intensive robotic systems in global healthcare markets.

The flagship product from SS Innovations is the SSi Mantra robotic surgical system. The hardware supports up to five modular robotic arms and addresses procedures in cardiac surgery, thoracic surgery, urology, gynecology, general surgery, gastro-intestinal surgery, and head and neck specialties. The broader ecosystem detailed on the official SS Innovations website includes SSi Mudra instruments, SSi Maya simulation software, SSi Yantra recording and streaming capabilities, and SSi Sutra accessories.

SS Innovations holds an Indian Central Drugs Standard Control Organisation (CDSCO) Manufacturing License (No. MFG/MD/2024/000827) and maintains European Committee for Standardization International Organization for Standardization (EN ISO) 13485:2016 quality management certification for medical devices. A financial profile published by Stock Analysis on NASDAQ:SSII notes that surgeons have completed more than 10,500 cumulative procedures using the SSi Mantra system.

Founder Background and the Access Motivation Behind SS Innovations

Dr. Sudhir Srivastava established SS Innovations following more than three decades of practice as a cardiothoracic surgeon specializing in minimally invasive techniques. During his surgical career, Dr. Srivastava completed more than 1,400 robotic operations, including more than 750 beating-heart totally endoscopic coronary artery bypass (TECAB) procedures. The official website for SS Innovations describes Dr. Srivastava as holding the surgical record for the highest volume of beating-heart TECAB operations performed globally. Dr. Srivastava also established the International College of Robotic Surgery to support clinical training.

Before establishing SS Innovations, Dr. Srivastava participated in the initial United States (US) clinical trials for the da Vinci robotic platform developed by Intuitive Surgical, which received United States Food and Drug Administration (FDA) approval in 2000. Dr. Srivastava subsequently relocated to India between 2011 and 2012 to establish local robotic cardiac surgery programs. In a detailed discussion on the Medsider podcast with Scott Nelson, Dr. Srivastava stated that his clinical work in India highlighted substantial distribution disparities in medical robotics.

In that interview, Dr. Srivastava stated that Intuitive Surgical held a near-monopoly that left roughly seven billion people across developing economies without access to robotic surgical technology. Dr. Srivastava committed approximately $4.5 million of his personal savings during early development before SS Innovations secured its initial outside funding round of $5 million in 2017.

Relative Cost Positioning Against Incumbent Robotics

SS Innovations positions the SSi Mantra surgical robot primarily on capital affordability and procedural economics. In the Medsider interview, Dr. Srivastava claimed that SS Innovations engineered the SSi Mantra system to sell at roughly one-third the purchase cost of Intuitive Surgical's top da Vinci model. Because neither manufacturer publishes standard public price catalogs, hospital procurement teams must treat this figure as the founder's commercial claim rather than an audited transaction benchmark.

SS Innovations designed the SSi Mantra cart to support up to five independent arms, differentiating it mechanically from traditional four-arm systems. The system also carries a stated focus on teaching and training, reflected in the SSi Maya simulation software.

Hospitals evaluating surgical equipment can compare these design choices against traditional consoles in the review of the da Vinci surgical system. Broader industry context on how equipment vendors structure capital purchases appears in the guide to medical robot companies and the directory of medical robot brands.

Public Funding History and Leadership Structure at SS Innovations

SS Innovations financed its research and product manufacturing through targeted private capital and public equity markets. In his Medsider interview, Dr. Srivastava explained that SS Innovations avoided taking hundreds of millions of dollars in single venture capital rounds. SS Innovations raised approximately $78 million to $80 million in cumulative financing prior to scaling commercial assembly.

SS Innovations trades publicly on the NASDAQ exchange under the ticker symbol SSII, as documented by Stock Analysis. This public listing provides quarterly financial reporting on cash reserves, inventory expenditures, and operating revenue for healthcare facilities and equity analysts reviewing the solvency of SS Innovations.

Dr. Srivastava confirmed in his Medsider conversation that Dr. Fred Moll is now part of SS Innovations. Dr. Moll previously co-founded Intuitive Surgical and later founded Auris Health, which Johnson and Johnson acquired. The founder did not specify Dr. Moll's exact executive title, and SS Innovations has not published further operational boundaries for that advisory role in the cited interview.

Global Commercial Footprint and Telesurgery Milestones

SS Innovations focused its initial commercial deployments across developing healthcare systems that face strict equipment budget constraints. In the Medsider interview, Dr. Srivastava noted that approximately 70 percent of the Indian customer base for SS Innovations operated in tier-2 and tier-3 regional cities rather than major metropolitan medical centers. At the time of that interview, SS Innovations held regulatory approvals across 15 countries and had installed operational SSi Mantra units in 12 of them.

More recent corporate data from Stock Analysis shows that commercial installations for SS Innovations now span India, the Philippines, Indonesia, the United Arab Emirates (UAE), and territories across South America. In his interview remarks, Dr. Srivastava noted that more than 120 countries globally do not require United States FDA clearance or a European Union (EU) Conformité Européenne (CE) mark to market medical devices, which enabled SS Innovations to generate commercial revenue ahead of Western regulatory clearances.

SS Innovations reached a domestic regulatory milestone in November 2024 when Indian medical device authorities granted approval for remote surgical operations, which Dr. Srivastava describes as the first such telesurgery approval. Following that decision, Dr. Srivastava reported completing what he characterized as the longest-distance telesurgical procedure on record, operating over a connection spanning approximately 20,000 kilometers between Guyana and a patient in India. Independent registries have not verified this clinical distance record, and healthcare institutions should evaluate the account as a manufacturer-reported demonstration.

Regarding Western market entry, SS Innovations did not hold United States FDA approval or a European CE mark at the time of the Medsider interview. Dr. Srivastava said SS Innovations was pursuing both and hoped to receive them later that year.